According to the results of a new international study, there may be a role for insulin-like growth factor-binding protein 4 (IGFBP4) in facilitating the interaction between macrophages and injured ...

A recent study published in Frontiers in Medicine described anti-post-translational modification (PTM) antibodies in patients with autoimmune-mediated and cholestatic liver diseases (AILD). Patients ...

CHMP positive opinion for Iqirvo® (elafibranor) recommended for the treatment of primary biliary cholangitis, following FDA approval in June 2024 CHMP positive opinion for Kayfanda® (odevixibat) ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Epidemiologically, PBC is more commonly ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

30. Seek and treat associated and alternate causes of fatigue, particularly anemia, hypothyroidism, and sleep disturbance (III, 1). 31. Advise patients with fatigue (which in some may be debilitating) ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi ® (seladelpar) ...

The US Food and Drug Administration (FDA) granted accelerated approval for Livdelzi (seladelpar, Gilead Sciences, Inc.) for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid ...

The accelerated approval was based primarily on data from the pivotal placebo-controlled Phase 3 RESPONSE study. In the study, 62% of participants taking Livdelzi achieved the primary endpoint of ...